<SEC-DOCUMENT>0001062993-14-002828.txt : 20140514
<SEC-HEADER>0001062993-14-002828.hdr.sgml : 20140514
<ACCEPTANCE-DATETIME>20140513174144
ACCESSION NUMBER:		0001062993-14-002828
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140507
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140514
DATE AS OF CHANGE:		20140513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51652
		FILM NUMBER:		14838607

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form 8K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR></B>Washington, D.C.
20549<B> </B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center>Current Report<BR>Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934</P>
<P align=center>Date of Report (Date of earliest event reported): <B><U>May 7,
2014 </U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
<BR></B>(Exact name of registrant as specified in its charter)</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-51652 </U></B></TD>
    <TD align=center width="33%"><B><U>20-8365999 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>of incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>51 West 52nd Street, 7th Floor, New York, NY USA 10019
<BR></U></B>(Address of principal executive offices) (Zip Code)</P>
<P align=center>Registrant's telephone number, including area code <b><u>1-844-689-3939</u></b></P>
<P align=center><B><U>Not Applicable <BR></U></B>(Former name or former address,
if changed since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </P>
<P align=justify>[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</P>
<P align=justify>[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)</P>
<P align=justify>[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))</P>
<P align=justify>[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.</B> </P>
<P align=justify>Effective May 7, 2014 (the &#147;<U>Effective Date</U>&#148; ), the board
of directors (the &#147;<U>Board</U>&#148; ) of Anavex Life Sciences Corp., a Nevada
corporation (the &#147;<U>Company</U>&#148; ), appointed Bernd Metzner and Elliot Favus to
serve as members of the Board until their successors are duly elected, qualified
and seated or until their earlier resignation or removal.</P>
<p>As compensation for his services, the Company granted Mr. Metzner  options to purchase one hundred fifty thousand (150,000) shares of common stock  in the Company, said options to vest annually over a three year period  commencing on the first anniversary of the Effective Date. In addition to being  a member of the Board, Mr. Metzner will serve as Chairman of the Audit  Committee as of the Effective Date and the Company agreed to pay Mr. Metzner  $2,500 per quarter commencing on the third quarter of fiscal year 2014.&nbsp; </p>
<P align=justify>As compensation for Mr. Favus&#146; services to the Board, the
Company granted Mr. Favus options to purchase one hundred fifty thousand
(150,000) shares of common stock in the Company, said options to vest annually
over a three year period commencing on the first anniversary of the Effective
Date.</P>
<P align=justify>On May 8, 2014 we announced the above-mentioned appointments in
a press release. Said press release is attached as an exhibit hereto.</P>
<P align=justify><B>Item 9.01.</B> <B>Financial Statements and Exhibits.
</B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>Not applicable</P></TD></TR>
  <TR>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify><U>Exhibits</U>.</P></TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center><B>EXHIBIT
      NO.</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="45%"><B>DESCRIPTION</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="45%"><B>LOCATION</B> </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="45%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated May 8,
      2014. </a></TD>
    <TD align=center width="45%" bgColor=#eeeeee><a href="exhibit99-1.htm">Provided herewith
    </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=center><B><U>SIGNATURES</U></B></P>
<P align=justify>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%"><B>ANAVEX LIFE SCIENCES CORP.</B> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%"><I><U>/s/ Christopher Missling</U></I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Name: Christopher Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Title: Chief Executive Officer </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Date: May 13, 2014 </TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=justify><B>Anavex Appoints Senior Healthcare and Pharmaceutical
Executives to Board of Directors </B></P>
<P align=justify><B>NEW YORK </B>(May 8, 2014) &#150; Anavex Life Sciences Corp.
(&#147;Anavex&#148; or the &#147;Company&#148;) (OTCQB: AVXL), a clinical-stage biopharmaceutical
company developing novel drug candidates to treat Alzheimer's disease, other
diseases of the central nervous system (CNS) and various types of cancer, today
announced the appointment of Bernd Metzner, PhD and Elliot Favus, MD to its
board of directors. Dr. Favus and Dr. Metzner join existing directors
Christopher U. Missling, PhD and Tom Skarpelos. </P>
<P align=justify>"As former Head of Finance of Bayer Schering Pharma AG with
corporate CFO responsibility at other large companies, Dr. Metzner has extensive
experience from early-stage research to commercialization of innovations. His
financial acumen will be invaluable to Anavex as we work to develop novel drugs
for the treatment of unmet medical needs in a range of diseases and advance
these potential therapies through clinical development," said Christopher U.
Missling, PhD, President and Chief Executive Officer of Anavex. "The expertise
that Dr. Favus brings to Anavex is exceptionally complementary. His significant
insights into successful business models and clinical trial and
commercialization strategies, developed through in-depth analysis of healthcare
companies, are expected to be extremely beneficial. On behalf of Anavex and the
Board of Directors, I welcome both Dr. Favus and Dr. Metzner and look forward to
drawing upon their strategic, operational and clinical judgment." </P>
<P align=justify><B>Bernd Metzner, PhD </B></P>
<P align=justify>Bernd Metzner, PhD is currently Chief Financial Officer of the
Doehler Group, a global producer and provider of technology-based natural
ingredients for the food and beverage industry with sales activities in more
than 130 countries. Previously, he was Chief Administration Officer and member
of the Board of Management of Bayer Schering Pharma AG, the pharmaceutical
division of $100+ billion market cap company Bayer AG. In this position, Dr.
Metzner had worldwide financial responsibility for the Bayer Pharma Group.
During his almost 10-years with Bayer AG, Dr. Metzner also held several senior
international management positions in the corporate finance organization of
Bayer AG, including Chief Financial Officer of Bayer S.p.A. Italy and heading
the coordination of the successful spin-off of Lanxess, a specialty chemicals
group. Dr. Metzner started his career at the law firm Flick Gocke Schaumburg and
has a degree in business administration from the University of Siegen. After
obtaining his doctorate, he became a chartered accountant.</P>
<P align=justify><B>Elliot Favus, MD</B></P>
<P align=justify>Elliot Favus, MD is Chief Executive Officer of Favus
Institutional Research, a healthcare research firm serving institutional
investors. He has been a healthcare equity research analyst on Wall Street since
2006, starting at Lazard Capital Markets and subsequently at Och-Ziff Capital
Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor
in medicine at Mount Sinai School of Medicine in New York. He attended the
University of Michigan (BA, 1996), the University of Chicago Pritzker School of
Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency
Program (2004). He is board-certified in Internal Medicine (2004) and has 10
years of basic science laboratory experience working on human genetics projects
at Harvard Medical School, the University of Chicago and the University of
Pittsburgh.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>About Anavex Life Sciences Corp.</B></P>
<P align=justify>Anavex Life Sciences Corp. (<U>www.anavex.com</U>) is a
  clinical-stage biopharmaceutical company engaged in the development of novel
  drug candidates to treat Alzheimer&#146;s disease, other CNS diseases and various
  types of cancer. ANAVEX 2-73, an orally available drug candidate developed to
  treat Alzheimer's disease through potential disease modification, has undergone
  an initial Phase 1 human clinical trial and was well tolerated in doses up to
  55mg. Results from preclinical studies indicate that ANAVEX 2-73 demonstrates
  anti-amnesic and neuroprotective properties. A highly encouraging synergistic
  effect has also been observed between ANAVEX 2-73 and donepezil (Aricept&#174;). The
  combined therapeutic, called ANAVEX PLUS produced up to 80% greater reversal of
  memory loss in Alzheimer&#146;s disease models versus when the drugs were used
  individually. Anavex is a publicly traded corporation quoted as AVXL. </P>
<P align=justify><B>Forward-Looking Statements</B></P>
<P align=justify>Statements in this press release that are not strictly
historical in nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a number
of risks and uncertainties. Actual events or results may differ materially from
those projected in any of such statements due to various factors, including the
risks set forth in the Company&#146;s most recent Annual Report on Form 10-K filed
with the SEC. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement and Anavex Life Sciences Corp. undertakes no obligation to revise or
update this press release to reflect events or circumstances after the date
hereof. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>For Further Information</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Anavex Life Sciences Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>Research &amp; Business Development </TD></TR>
  <TR vAlign=top>
    <TD align=left>Email: <U>info@anavex.com</U> </TD></TR>
  <TR>
    <TD>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>Shareholder &amp; Media Relations </TD></TR>
  <TR vAlign=top>
    <TD align=left>Toll-free: 1-866-505-2895 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Outside North America: +1 (416) 489-0092 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Email: <U>ir@anavex.com</U> </TD></TR>
  <TR vAlign=top>
    <TD align=left><U>www.anavex.com</U> </TD></TR></TABLE>
<P align=center># # # </P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
